Biotech Group Unveils Plan to Lead Global Race
The Biotechnology Innovation Organization released a seven-point national action plan aimed at keeping U.S. biotech leadership ahead of China.
Updated on Nov. 10, 2026 in Biotech

Live Poll
Should the U.S. increase federal funding for biomedical research to compete with China?
The Biotechnology Innovation Organization released BioAdvance: Securing America's Biotech Century on November 10, 2026, a national action plan with seven actionable priorities across three areas: coordinate, accelerate, and build. The plan responds to China's effort to become the world's leading biotechnology power.
Why it matters
China's competition in biotechnology poses challenges to health, the economy, and national security, making the outcome relevant to Americans nationwide. The plan frames the U.S. bioscience sector as a strategic asset that must be sustained.
The U.S. bioscience industry employed more than 2.3 million Americans and generated nearly $3.2 trillion in economic output by 2025, across roughly 156,000 business establishments. China's biotechnology industry value grew more than 100-fold between 2016 and 2021, and the plan does not yet address how the gap will be measured going forward.
The players
Biotechnology Innovation Organization
The Biotechnology Innovation Organization is a trade group representing biotechnology companies and research institutions that advocates for industry policy in the United States.
The details
The plan calls for establishing a White House Office of Biotechnology and expanding U.S. biomanufacturing capacity while sustaining support for biomedical research. It also proposes speeding the path to first-in-human clinical studies and modernizing drug development.
Timeline
November 10, 2026: BIO released the BioAdvance national action plan.
2016-2021: China's biotechnology industry value grew more than 100-fold.
2025: U.S. bioscience employment and economic output figures were reported.
Big Picture
China has directed massive state resources toward biotechnology in every new five-year plan, and the BioAdvance proposal answers that pattern with a coordinated U.S. strategy. The plan positions American biotech policy as a direct response to Beijing's documented industrial push.
The plan's proposals could affect how quickly new drugs move from research into clinical trials. Its emphasis on biomanufacturing capacity also points to where future production jobs and investment may be located.
The takeaway
Biotechnology leadership depends on coordinated policy across government and industry, not on research strength alone. Watching how Congress responds to the proposed White House office will show whether the plan moves beyond recommendation.
Further reading
Explore more on Biotech developments shaping the United States' position in the global race.
Live Poll
Should the U.S. increase federal funding for biomedical research to compete with China?






